D octors face an impossible task in appraising, synthesising, and regularly revisiting the evidence, even in a relatively small field such as neuromuscular disease. Randomised controlled trials are the most powerful tool for assessing and comparing the efficacy of different interventions. 1 With the possible exceptions of interventions with very large or very small effect sizes, 2 3 they provide the best research design to address questions of therapeutic efficacy. Properly designed randomised controlled trials minimise selection bias by ensuring the homogeneity of the comparison groups from the very start of the trial. Interventions for neuromuscular disease need testing in randomised trials as much as interventions in any other field. However, most neuromuscular diseases are uncommon so that collecting sufficient patients to answer even simple questions about interventions with moderate effects is difficult.
c MINIMISING BIAS
Conventional reviews of treatment risk bias from failure to identify all trials, inclusion of flawed trials, the personal opinion of the author and, often, lack of peer review. The Cochrane Collaboration, which was established in 1992, has been at the forefront of the effort to develop methods for systematic reviewing which minimise bias. 4 5 Methods adopted by the Cochrane Neuromuscular Disease Group to minimise bias include: c authorship of reviews by individuals from more than one institution c peer review and prior publication of the methods for the review in a protocol, which is available for criticism or comment by anyone interested c a comprehensive search for randomised controlled trials in all languages (box 1) c independent quality assessment by at least two reviewers (box 2) c independent data extraction by two reviewers on specially designed data extraction forms c contact with authors of trial reports to obtain missing data c a rigorous peer review and editing process c the facility for readers to comment on reviews after publication, and publication of authors' response to comments c regular updating of reviews (at least every two years).
Where appropriate, the results are combined in a single statistical expression of the efficacy of the treatment, or meta-analysis. Although Cochrane reviews for the most part focus on reviewing the randomised evidence, our group likes this put in the context of other relevant research and published expert opinion. The discussion should also consider adverse events and health economic factors which are rarely adequately dealt with in randomised trials.
Cochrane reviews have been shown to be less biased and more systematic than systematic reviews published in traditional medical journals. 6 7 
COCHRANE NEUROMUSCULAR DISEASE GROUP
The Cochrane Neuromuscular Disease Group has the responsibility for reviewing the whole range of neuromuscular diseases, including disorders of the muscle, neuromuscular junction, peripheral nervous system, and lower motor neuron. We cover all interventions including prevention, acute treatment, and rehabilitation. Box 3 contains a list of 19 published reviews. We have identified over 170 interventions requiring review. If you would like to contribute to this task or have questions, please contact the coordinator, Cochrane Neuromuscular Disease Group (kate.jewitt@kcl.ac.uk and website http://www.kcl.ac.uk/cochranenmd).
